BioElectronics Announces Publication of Patent Application
RF Induced Thermal Treatment of Tissue Pain
FREDERICK, Md., Feb. 26, 2013 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of unique inexpensive, patented, anti-inflammatory pain reliever devices, announced today that the World Intellectual Property Organization has published the International Patent Application for RF Induced Thermal Treatment of Tissue Pain.
While pulsed shortwave therapy is an established medical therapy, this patent provides for a method to subcutaneously heat body tissue, our nine (9) other approved, and eight (8) pending are for a self-contained medical device that is affixed to the body with a flexible antenna that allows the patient to move more freely. This low power extended duration therapy is 3x's better than heating pads, 100% safer and costs less than $0.25 for overnight pain relief.
"We appreciate the importance of protecting our intellectual property throughout the world," said John Martinez, Director of Engineering at BioElectronics. "This patent and our portfolio of patents provide confirmation of our sound science and are valuable assets in our accumulated body of knowledge."
About BioElectronics Corporation
Drugs and heat patches provide temporary minimal pain relief by simply masking it but it always comes back. ActiPatch provides 5x better pain relief and is 100% safer than over-the-counter drugs. BioElectronics Corporation is an award winning medical device developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal complaints, the Allay™ menstrual cycle pain therapy, and RecoveryRx™ for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective in-home option to reduce soft tissue pain and inflammation, and to accelerate healing. For more information, please see www.bielcorp.com.
Contact:
Paul Knopick
940.262.3584
[email protected]
SOURCE BioElectronics Corporation
Share this article